Atorvastatin upregulates apolipoprotein M expression via attenuating LXRα expression in hyperlipidemic apoE‑deficient mice

Liu,Jian; Huang,Haoyue; Shi,Sheng; Wang,Xu; Yu,Yunsheng; Hu,Yanqiu; Sun,Jiacheng; Ren,Chuanlu; Yang,Junjie; Shen,Zhenya

doi:10.3892/etm.2018.6694

Atorvastatin upregulates apolipoprotein M expression via attenuating LXRα expression in hyperlipidemic apoE‑deficient mice

Authors:
- Jian Liu
- Haoyue Huang
- Sheng Shi
- Xu Wang
- Yunsheng Yu
- Yanqiu Hu
- Jiacheng Sun
- Chuanlu Ren
- Junjie Yang
- Zhenya Shen
View Affiliations

Affiliations: Department of Cardiovascular Surgery, The First Affiliated Hospital and Institute for Cardiovascular Science, Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Clinical Laboratory, The 100th Hospital of The People's Liberation Army, Suzhou, Jiangsu 215000, P.R. China
Published online on: September 4, 2018 https://doi.org/10.3892/etm.2018.6694
Pages: 3785-3792
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Apolipoprotein M (apoM) is a recently identified human apolipoprotein that is associated with the formation of high‑density lipoprotein (HDL). Studies have demonstrated that statins may affect the expression of apoM; however, the regulatory effects of statins on apoM are controversial. Furthermore, the underlying mechanisms by which statins regulate apoM remain unclear. In the present study, in vivo and in vitro models were used to investigate whether the anti‑atherosclerotic effects of statins are associated with its apoM‑regulating effects and the underlying mechanism. Hyperlipidemia was induced by in apolipoprotein E‑deficient mice by providing a high‑fat diet. Atorvastatin was administered to hyperlipidemic mice and HepG2 cells to investigate its effect on apoM expression. The liver X receptor α (LXRα) agonist T0901317 was also administered together with atorvastatin to hyperlipidemic mice and HepG2 cells. The results revealed that atorvastatin increased apoM expression, which was accompanied with decreased expression of LXRα in the liver of hyperlipidemic apolipoprotein E‑deficient mice and HepG2 cells. Additionally, apoM upregulation was inhibited following treatment with T0901317. In summary, atorvastatin exhibited anti‑atherosclerotic effects by upregulating apoM expression in hyperlipidemic mice, which may be mediated by the inhibition of LXRα.

View Figures

View References

1	Ma T, Sun J, Zhao Z, Lei W, Chen Y, Wang X, Yang J and Shen Z: A brief review: Adipose-derived stem cells and their therapeutic potential in cardiovascular diseases. Stem Cell Res Ther. 8:1242017. View Article : Google Scholar : PubMed/NCBI
2	Marenberg ME, Risch N, Berkman LF, Floderus B and de Faire U: Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 330:1041–1046. 1994. View Article : Google Scholar : PubMed/NCBI
3	Nora JJ, Lortscher RH, Spangler RD, Nora AH and Kimberling WJ: Genetic-epidemiologic study of early-onset ischemic heart disease. Circulation. 61:503–508. 1980. View Article : Google Scholar : PubMed/NCBI
4	Manting L, Haihong Z, Jing L, Shaodong C and Yihua L: The model of rat lipid metabolism disorder induced by chronic stress accompanying high-fat-diet. Lipids Health Dis. 10:1532011. View Article : Google Scholar : PubMed/NCBI
5	Ren K, Tang ZL, Jiang Y, Tan YM and Yi GH: Apolipoprotein M. Clin Chim Acta. 446:21–29. 2015. View Article : Google Scholar : PubMed/NCBI
6	Kappelle PJ, Ahnstrom J, Dikkeschei BD, de Vries R, Sluiter WJ, Wolffenbuttel BH, van Tol A, Nielsen LB, Dahlbäck B and Dullaart RP: Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus. Atherosclerosis. 213:247–250. 2010. View Article : Google Scholar : PubMed/NCBI
7	Ye YZ, Cao B, Li MQ, Wang W, Wang RX, Rui J, Wei LY, Jing ZH, Ji Y, Jiao GQ and Zou J: Dihydrotestosterone regulating apolipoprotein M expression mediates via protein kinase C in HepG2 cells. Lipids Health Dis. 11:1682012. View Article : Google Scholar : PubMed/NCBI
8	Su W, Jiao G, Yang C and Ye Y: Evaluation of apolipoprotein M as a biomarker of coronary artery disease. Clin Biochem. 42:365–370. 2009. View Article : Google Scholar : PubMed/NCBI
9	Wolfrum C, Poy MN and Stoffel M: Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med. 11:418–422. 2005. View Article : Google Scholar : PubMed/NCBI
10	Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH and Dahlback B: Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res. 47:1833–1843. 2006. View Article : Google Scholar : PubMed/NCBI
11	Endo A: A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 86:484–493. 2006. View Article : Google Scholar
12	Tsai NW, Lee LH, Huang CR, Chang WN, Chang YT, Su YJ, Chiang YF, Wang HC, Cheng BC, Lin WC, et al: Statin therapy reduces oxidized low density lipoprotein level, a risk factor for stroke outcome. Crit Care. 18:R162014. View Article : Google Scholar : PubMed/NCBI
13	Al-Ghoul WM, Kim MS, Fazal N, Azim AC and Ali A: Evidence for simvastatin anti-inflammatory actions based on quantitative analyses of NETosis and other inflammation/oxidation markers. Results Immunol. 4:14–22. 2014. View Article : Google Scholar : PubMed/NCBI
14	Schmidt M, Cannegieter SC, Johannesdottir SA, Dekkers OM, Horváth-Puhó E and Sorensen HT: Statin use and venous thromboembolism recurrence: A combined nationwide cohort and nested case-control study. J Thromb Haemost. 12:1207–1215. 2014. View Article : Google Scholar : PubMed/NCBI
15	Paraskevaidis IA, Iliodromitis EK, Ikonomidis I, Rallidis L, Hamodraka E, Parissis J, Andoniadis A, Tzortzis S and Anastasiou-Nana M: The effect of acute administration of statins on coronary microcirculation during the pre-revascularization period in patients with myocardial infraction. Atherosclerosis. 223:184–189. 2012. View Article : Google Scholar : PubMed/NCBI
16	Yang L and Zhao S: Effect of simvastatin on the expression and regulation mechanism of apolipoprotein M. Int J Mol Med. 29:510–514. 2012.PubMed/NCBI
17	Zhang X, Mao S, Luo G, Wei J, Berggren-Söderlund M, Nilsson-Ehle P and Xu N: Effects of simvastatin on apolipoprotein M in vivo and in vitro. Lipids Health Dis. 10:1122011. View Article : Google Scholar : PubMed/NCBI
18	Ulven SM, Dalen KT, Gustafsson JA and Nebb HI: LXR is crucial in lipid metabolism. Prostaglandins Leukot Essent Fatty Acids. 73:59–63. 2005. View Article : Google Scholar : PubMed/NCBI
19	Zhang Y and Mangelsdorf DJ: LuXuRies of lipid homeostasis: The unity of nuclear hormone receptors, transcription regulation, and cholesterol sensing. Mol Interv. 2:78–87. 2002. View Article : Google Scholar : PubMed/NCBI
20	Houck KA, Borchert KM, Hepler CD, Thomas JS, Bramlett KS, Michael LF and Burris TP: T0901317 is a dual LXR/FXR agonist. Mol Genet Metab. 83:184–187. 2004. View Article : Google Scholar : PubMed/NCBI
21	Wong J, Quinn CM and Brown AJ: Statins inhibit synthesis of an oxysterol ligand for the liver × receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol. 24:2365–2371. 2004. View Article : Google Scholar : PubMed/NCBI
22	Zhang X, Zhu Z, Luo G, Zheng L, Nilsson-Ehle P and Xu N: Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro. Biochem Biophys Res Commun. 371:114–117. 2008. View Article : Google Scholar : PubMed/NCBI
23	Gervois P, Fruchart JC and Staels B: Drug Insight: Mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab. 3:145–156. 2007. View Article : Google Scholar : PubMed/NCBI
24	Zhang Y, Lei W, Yan W, Li X, Wang X, Zhao Z, Hui J, Shen Z and Yang J: microRNA-206 is involved in survival of hypoxia preconditioned mesenchymal stem cells through targeting Pim-1 kinase. Stem Cell Res Ther. 7:612016. View Article : Google Scholar : PubMed/NCBI
25	Zhang Z, Yang J, Yan W, Li Y, Shen Z and Asahara T: Pretreatment of cardiac stem cells with exosomes derived from mesenchymal stem cells enhances myocardial repair. J Am Heart Assoc. 5:e0028562016. View Article : Google Scholar : PubMed/NCBI
26	You J, Sun J, Ma T, Yang Z, Wang X, Zhang Z, Li J, Wang L, Ii M, Yang J and Shen Z: Curcumin induces therapeutic angiogenesis in a diabetic mouse hindlimb ischemia model via modulating the function of endothelial progenitor cells. Stem Cell Res Ther. 8:1822017. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Friesen JA and Rodwell VW: The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol. 5:2482004. View Article : Google Scholar : PubMed/NCBI
29	Bonetti PO, Lerman LO, Napoli C and Lerman A: Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J. 24:225–248. 2003. View Article : Google Scholar : PubMed/NCBI
30	Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Rössig L, Heeschen C, Dimmeler S and Zeiher AM: Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: Clinical evidence for ‘pleiotropic’ functions of statin therapy. Eur Heart J. 27:1182–1190. 2006. View Article : Google Scholar : PubMed/NCBI
31	Cortellaro M, Cofrancesco E, Arbustini E, Rossi F, Negri A, Tremoli E, Gabrielli L and Camera M: Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: The ATROCAP study. Thromb Haemost. 88:41–47. 2002. View Article : Google Scholar : PubMed/NCBI
32	Otto C, Geiss HC, Empen K and Parhofer KG: Long-term reduction of C-reactive protein concentration by regular LDL apheresis. Atherosclerosis. 174:151–156. 2004. View Article : Google Scholar : PubMed/NCBI
33	Luzak B, Boncler M, Rywaniak J, Wilk R, Stanczyk L, Czyz M, Rysz J and Watala C: The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients. Eur J Pharmacol. 658:91–97. 2011. View Article : Google Scholar : PubMed/NCBI
34	Xu N and Dahlbäck B: A novel human apolipoprotein (apoM). J Biol Chem. 274:31286–31290. 1999. View Article : Google Scholar : PubMed/NCBI
35	Zhang XY, Dong X, Zheng L, Luo GH, Liu YH, Ekström U, Nilsson-Ehle P, Ye Q and Xu N: Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem. 105:67–72. 2003. View Article : Google Scholar : PubMed/NCBI
36	Richter S, Shih DQ, Pearson ER, Wolfrum C, Fajans SS, Hattersley AT and Stoffel M: Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: Haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes. 52:2989–2995. 2003. View Article : Google Scholar : PubMed/NCBI
37	Elsoe S, Christoffersen C, Luchoomun J, Turner S and Nielsen LB: Apolipoprotein M promotes mobilization of cellular cholesterol in vivo. Biochim Biophys Acta. 1831:1287–1292. 2013. View Article : Google Scholar : PubMed/NCBI
38	Mulya A, Seo J, Brown AL, Gebre AK, Boudyguina E, Shelness GS and Parks JS: Apolipoprotein M expression increases the size of nascent pre beta HDL formed by ATP binding cassette transporter A1. J Lipid Res. 51:514–524. 2010. View Article : Google Scholar : PubMed/NCBI
39	Christoffersen C, Jauhiainen M, Moser M, Porse B, Ehnholm C, Boesl M, Dahlbäck B and Nielsen LB: Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem. 283:1839–1847. 2008. View Article : Google Scholar : PubMed/NCBI